What does this research mean for the field?

PRN1008, a novel reversible covalent Bruton's tyrosine kinase inhibitor, is safe, well-tolerated, and achieves high, sustained target occupancy in healthy volunteers following oral administration. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

June 21, 2017British Journal of Clinical PharmacologyOpen Access

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

View Full Paper

Ask AI

Bookmark

Authors

PSPatrick F. Smith JKJanakan Krishnarajah PNPhilip A. Nunn

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smith et al. (2017) studied this question.

synapsesocial.com/papers/6a28efc24beb51dead9fedec https://doi.org/10.1111/bcp.13351

View Full Paper

Ask AI

Bookmark

June 21, 2017British Journal of Clinical PharmacologyOpen Access

A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers

View Full Paper

Ask AI

Bookmark

Authors

PSPatrick F. Smith JKJanakan Krishnarajah PNPhilip A. Nunn

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Smith et al. (2017) studied this question.

synapsesocial.com/papers/6a28efc24beb51dead9fedec https://doi.org/10.1111/bcp.13351

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark